DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phenobarbital (Phenobarbital) - Summary



The barbiturates are nonselective central nervous system (CNS) depressants that are primarily used as sedative-hypnotics. In subhypnotic doses, they are also used as anticonvulsants. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act.

PHENOBARBITAL (Phenobarbital) is indicated for the following:

A. Sedative

B. Anticonvulsant

For the treatment of generalized and partial seizures.

See all Phenobarbital indications & dosage >>


Published Studies Related to Phenobarbital

Current position of phenobarbital in epilepsy and its future. [2012]
This article reviews the current position of phenobarbital using articles published since 2000 and speculates on its likely future contribution to epilepsy care. Over the last decade there have been no major double-blind randomized placebo-controlled or comparative trials with phenobarbital.All these data predict a healthy future for phenobarbital, particularly in helping to close the treatment gap in low- and middle-income countries during its second century of clinical use.

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. [2010]
The objective of the study described here was to evaluate the efficacy, tolerability, and cognitive effects of levetiracetam (LEV) in patients with seizures and Alzheimer's disease (AD). This was a prospective, randomized, three-arm parallel-group, case-control study of 95 patients taking LEV (n=38), phenobarbital (PB) (n=28), and lamotrigine (LTG) (n=29)...

A randomized, triple-blind, placebo-controlled trial of prophylactic oral phenobarbital to reduce the need for phototherapy in G6PD-deficient neonates. [2005]
phototherapy among G6PD-deficient neonates... CONCLUSION: Prophylactic oral phenobarbital does not decrease the need for

Effects of phenobarbital and multiple-dose corticosteroids on developmental outcome at age 7 years. [2003]
outcomes (behavior and head circumference) at age 7 years... CONCLUSION: Antenatal phenobarbital and repetitive antenatal corticosteroid

Does perinatal phenobarbital exposure affect developmental outcome at age 2? [1999]
The objective of this paper is to determine if phenobarbital exposure during pregnancy affects developmental outcome at age 2 years. Between 1991 and 1994, 401 pregnant patients at risk for delivery prior to 34 weeks' gestation were invited to participate; 48 mothers declined entry... It was concluded that perinatal phenobarbital therapy may impair developmental outcome.

more studies >>

Clinical Trials Related to Phenobarbital

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage [Completed]
This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.

Prophylactic Phenobarbital After Neonatal Seizures [Terminated]
The treatment of infants with medications after their seizures have stopped is very variable. No one knows if continuing treatment with phenobarbital for up to several months is helpful or harmful. This clinical trial is designed to help answer that question and provide data that will help determine standard of care for these children.

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures [Active, not recruiting]

Phenobarbital for Acute Alcohol Withdrawal [Completed]
Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based alcohol withdrawal protocol will be associated with decreased need for ICU admission, continuous lorazepam infusion and will not be associated with increased adverse events.

Study of Phenobarbital Inhibition of Catamenial Epilepsy [Withdrawn]
The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy. We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.

more trials >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017